A Prospective, Multicenter,Single Arm Clinical Investigation Evaluating Safety and Effectiveness of the Flow Diverter for Treating Patients With Intracranial Aneurysms
the Flow Diverter
Anévrisme+6
+ Maladies du cerveau
+ Maladies Cardiovasculaires
Étude thérapeutique
Résumé
Date de début de l'étude : 17 octobre 2021
Date à laquelle le premier participant a commencé l'étude.To evaluate the efficacy and safety of the blood flow guide device manufactured by Jiangsu Changyida Medical Technology Co., Ltd. for endovascular embolization of intracranial aneurysms
Protocole
Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.166 participants à inclure
Nombre total de participants que l'essai clinique vise à recruter.Traitement
Éligibilité
Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.Tout sexe
Le sexe biologique des participants éligibles à s'inscrire.De 18 à 75 ans
Tranche d'âge des participants éligibles à participer.Volontaires sains non autorisés
Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.Conditions
Pathologie
Critères
Inclusion Criteria: ●≥18 years old and ≤75 years old, male or unpregnant female * Untreated and unruptured intracranial wide-necked aneurysm confirmed by preoperative imaging diagnosis (wide-necked aneurysm was defined as the tumor neck ≥4mm or the tumor body/tumor neck ratio \<2) * The target aneurysm is planned to be treated with blood flow guidance device only, without the need to complete the treatment by stages * The width of tumor neck should be less than 30mm * Imaging measurements of the tumor parent artery showed that the diameter was 1.5mm \~ 6.5mm * The subject or legal guardian can understand the purpose of the study, demonstrate sufficient compliance with the study protocol, and sign the informed consent Exclusion Criteria: * The target aneurysm has previously received craniotomy clipping or other endovascular interventional treatment * Target aneurysms were haemacular aneurysms, pseudoaneurysms, arteriovenous malformations and moyamoya disease related aneurysms * DSA suggested vascular path tortuosity or severe arteriosclerosis, and it was difficult for the instrument to reach the target vessel * Contraindications to dual antiplatelet therapy and anticoagulation therapy * Patients with known clear allergy to nickel-titanium alloys and platinum-tungsten alloys * People with known severe allergy to contrast media (excluding rash) * patients with known dementia or mental illness * Preoperative complicated with serious heart, liver, kidney, respiratory system diseases and bleeding disorders * Life expectancy is less than one year * Is participating in, or may participate in, any other drug or medical device clinical trial after inclusion in this clinical trial * Other conditions determined by the investigator to be unsuitable for participation in this clinical trial
Plan de l'étude
Découvrez tous les traitements administrés dans cette étude, leur description détaillée et ce qu'ils impliquent.Un seul groupe d'intervention est désigné dans cette étude
Cette étude ne comporte pas de groupe placebo.
Groupes de traitement
Groupe I
Objectifs de l'étude
Objectifs principaux
Objectifs secondaires